Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: A review comparing it with other fluoropyrimidine-based therapies

OncoTargets and Therapy

Volumn 4, Issue , 2011, Pages 193-201

  Kobayakawa, Masao ^a   Kojima, Yasushi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Chemotherapy; Fluoropyrimidine; Gastric cancer; S 1

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; SORAFENIB; TRASTUZUMAB;

ADVANCED CANCER; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CONTINUOUS INFUSION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; ETHNIC DIFFERENCE; FATIGUE; FEBRILE NEUTROPENIA; GASTRECTOMY; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPOKALEMIA; INTESTINE INJURY; JAPAN; LEUKOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 84873547505     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S19059     Document Type: Article

References (45)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
2. Garcia M, Jemal A, Ward EM, Hao Y, Siegel RL, Thun MJ. Global Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007.
3. Cullinan SA, Moertel CG, Wieand HS, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol. 1994;12(2):412-416.
4. Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993;71(12):3813-3818.
5. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003;21(1):54-59.
6. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261-267.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991-4997.
8. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265(10):1287-1289.
9. ICH Expert Working Group. Ethnic factors in the acceptability of foreign clinical data E5(R1). February 5, 1998. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdf. Accessed October 7, 2011.
10. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet. 2006;45(3): 235-252.
11. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour inhibitory compounds. Nature. 1957;179(4561):663-666.
12. Grem JL. 5-Fluoropyrimidines. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1996:149-211.
13. Fraile RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res. 1980;40(7):2223-2228.
14. Bajetta E, Colleoni M, Di Bartolomeo M, et al. Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. J Clin Oncol. 1995;13(10):2613-2619.
15. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16(1):301-308.
16. Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB, Van Gennip AH, Gonzalez FJ. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol. 1995;14(1):1-6.
17. Shirasaka T, Shimamoto Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7(5): 548-557.
18. El-Sayed YM, Sadee W. Metabolic activation of ftorafur [R,S-1- (tetrahyro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway. Biochem Pharmacol. 1982;31(18):3006-3008.
19. Nakajima M, Fukami T, Yamanaka H, et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther. 2006;80(3): 282-297.
20. Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P450 2A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica. 1996;26(4):395-403.
21. Hirose T, Fujita K, Nishimura K, et al. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. Oncol Rep. 2010;24(2):529-536.
22. Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol. 2008;26(13):2118-2123.
23. Sugimachi K, Maehara Y, Horikoshi N, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology. 1999;57(3): 202-210.
24. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34(11):1715-1720.
25. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology. 2000;58(3):191-197.
26. Boku N, Yamamoto S, Shirao K, et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer. (JCOG9912) [abstract]. J Clin Oncol. 2007;25 Suppl 18:LBA4513.
27. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89(12):2207-2212.
28. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215-221.
29. Nakahara H, Iishi H, Imamura H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP- 002). Gastric Cancer. 2011;14(1):72-80.
30. Kim YH, Koizumi W, Lee KH, et al. Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): the START trial [abstract]. J Clin Oncol. 2011;29 Suppl 4:7.
31. Asan Medical Center. Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer (SOS). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). June 5, 2009 [updated on September 26, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00915382. NLM identifier: NCT00915382.
32. Ajani JA, Faust J, Ikeda K, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005;23(28):6957-6965.
33. Lenz HJ, Lee FC, Haller DG, et al. Expanded safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 2007;109(1):33-40.
34. Ajani JA, Lee FC, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24(4):663-667.
35. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547-1553.
36. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810-1820.
37. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908-914.
38. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-Operative Group. Br J Cancer. 1999;79(9-10):1522-1530.
39. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453-462.
40. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first line therapy patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666-673.
41. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.
42. Lee JL, Kang YK, Kang HJ, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer. 2008;99(4):584-590.
43. Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC) [abstract]. J Clin Oncol. 2010;28 Suppl 18:LBA4007.
44. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697.
45. Okines AF, Ashley SE, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-f inding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol. 2010;28(25):3945-3950.